As FDA-approved anti-AD drugs in clinical practice, acetylcholinesterase inhibitors (AChEIs) and N-methyl-D-aspartic acid (NMDA) receptor antagonists only provide partial symptomatic improvement [7]. The gene discussed is ACHE; the disease is Alzheimer disease.